Procedures
cough, low immunoinflammatory stress, fever
Participants who met the inclusion criteria were assigned to intervention with nanocrystallized fenofibrate (TriCor, AbbVie Inc, North Chicago, IL USA) at a dose of 145 mg (1 tablet) once per day. Standard care for severe-hospitalized COVID-19 patients was provided according to local practice: antiviral treatment, vitamin D3, low-dose glucocorticoids, convalescent plasma, and supportive care as well as antipyretics for symptoms of fever (products containing paracetamol, or non-steroidal anti-inflammatories such as aspirin and ibuprofen) and dextromethorphan for symptoms of cough. Standard chronic treatments were continued unless COVID-19, clinical status, or fenofibrate treatment was a contraindication for treatment. Control patients were collected from the observational study’s database and filtered to patients that met the inclusion criteria, admitted with low immunoinflammatory stress (NLR <10 at admission), and treated according to the standard care used in the interventional study.